Mesenchymal stem cell-derived extracellular vesicles/exosome: A promising therapeutic strategy for intracerebral hemorrhage

Regen Ther. 2023 Feb 18:22:181-190. doi: 10.1016/j.reth.2023.01.006. eCollection 2023 Mar.

Abstract

Intracerebral hemorrhage (ICH) is the second largest type of stroke with high mortality and morbidity. The vast majority of survivors suffer from serious neurological defects. Despite the well-established etiology and diagnose, there is still some controversy over the ideal treatment strategy. MSC-based therapy has become an attractive and promising strategy for the treatment of ICH through immune regulation and tissue regeneration. However, accumulating studies have revealed that MSC-based therapeutic effects are mainly attributed to the paracrine properties of MSC, especially small extracellular vesicles/exosome (EVs/exo) which are considered to be the key mediators of the protective efficacy from MSCs. Moreover, some papers reported that MSC-EVs/exo have better therapeutic effects than MSCs. Therefore, EVs/exo has become a new choice for the treatment of ICH stroke in recent years. In this review, we mainly concentrate on the current research progress on the use of MSC-EVs/exo in the treatment of ICH and the existing challenges in their transplation from lab to clinical practice.

Keywords: CAA, Cerebral amyloid angiopathy; Cell free therapy; EVs, extracellular vesicles; Exo, exosome; Exosomes; Extracellular vesicles; ICH, Intracerebral hemorrhage; Intracerebral hemorrhage; MSCs, Mesenchymal stromal cells; Mechanism; SAH, subarachnoid hemorrhage; db-ICH, Intracerebral hemorrhage (ICH) induced by diabetes.

Publication types

  • Review